NEXIEN BIOPHARMA, INC. Quarterly Debt-to-equity in % from Q3 2015 to Q4 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Nexien Biopharma, Inc. quarterly Debt-to-equity history and growth rate from Q3 2015 to Q4 2024.
Nexien Biopharma, Inc. Debt-to-equity for the quarter ending December 31, 2024 was -102 %, a 8.91% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q4 2024	-102	+9.94	+8.91%	Dec 31, 2024
Q3 2024	-102	+18.7	+15.5%	Sep 30, 2024
Q2 2024	-103	+30.2	+22.6%	Jun 30, 2024
Q1 2024	-107	+44.4	+29.3%	Mar 31, 2024
Q4 2023	-112			Dec 31, 2023
Q3 2023	-121			Sep 30, 2023
Q2 2023	-134			Jun 30, 2023
Q1 2023	-151			Mar 31, 2023
Q2 2017	106	+206		Jun 30, 2017
Q1 2017	-100	0	0%	Mar 31, 2017
Q4 2016	-100	-1.85	-1.89%	Dec 31, 2016
Q3 2016	-100	-2.04	-2.08%	Sep 30, 2016
Q2 2016	-100			Jun 30, 2016
Q1 2016	-100			Mar 31, 2016
Q4 2015	-98.2			Dec 31, 2015
Q3 2015	-98			Sep 30, 2015

* An asterisk sign (*) next to the value indicates that the value is likely invalid.